<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945746</url>
  </required_header>
  <id_info>
    <org_study_id>HSJ_Dispersion Stability_2021</org_study_id>
    <nct_id>NCT04945746</nct_id>
  </id_info>
  <brief_title>Dispersion Stability</brief_title>
  <official_title>Study Evaluating the Prioritization of Ablation Zones According to the Stability of the Dispersion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the acute efficacy of ablation of the most stable VX1 areas (levels 2 and 3) in&#xD;
      terms of the rate of acute AF termination.&#xD;
&#xD;
      Identify the spatial distribution of dispersion stability levels based on VX1. Document the&#xD;
      rate of adverse events. To assess the long-term efficacy of ablation of the most stable VX1&#xD;
      areas in terms of the absence of documented arrhythmias during a 12-month follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF termination rate after ablation of the most stable regions (levels 3 and 2)</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>sinus rhythm at the end of the procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Software VX1 + Stability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Utilization of the software VX1 + Stability</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named &quot;stability&quot;).</description>
    <arm_group_label>Software VX1 + Stability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older candidates with Persistent or long-standing&#xD;
             persistent AF with documentation of (ECG, Holter, physician's letter):&#xD;
&#xD;
               -  AF duration of ≥ 3 months and ≤ 5 years or&#xD;
&#xD;
               -  1 effective cardioversion followed by AF recurrence lasting ≥ 3 months&#xD;
&#xD;
          2. Continuous anticoagulation with warfarin (INR 2-3) or NOAC for &gt; 4 weeks prior to&#xD;
             ablation&#xD;
&#xD;
          3. Patients must be able and willing to provide written informed consent to participate&#xD;
             in the clinical trial&#xD;
&#xD;
          4. Maximum of 50% of patients (13 patients) in persistent AF &lt; 12 months (&gt;30% of&#xD;
             long-standing persistent AF ≥ 12 months)&#xD;
&#xD;
          5. Being affiliated to a social security scheme or beneficiary of such a scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Paroxysmal and short-standing persistent AF &lt; 3 months&#xD;
&#xD;
          2. Severe obesity (BMI &gt; 45)&#xD;
&#xD;
          3. LA thrombus on Transesophageal Echocardiography (TEE) prior to procedure&#xD;
&#xD;
          4. Contraindications to anticoagulation (heparin, warfarin or NOAC)&#xD;
&#xD;
          5. Patients who are or may potentially be pregnant&#xD;
&#xD;
          6. Any cardiac surgery within the past 2 months (60 days) (includes PCI)&#xD;
&#xD;
          7. Myocardial infarction within the past 2 months (60 days)&#xD;
&#xD;
          8. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
          9. Documented thromboembolic event (including TIA) within the past 12 months (365 days)&#xD;
&#xD;
         10. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months&#xD;
             (365 days)&#xD;
&#xD;
         11. Unstable angina within the past month&#xD;
&#xD;
         12. Acute illness or active systemic infection or sepsis (including COVID 19)&#xD;
&#xD;
         13. Enrollment in an investigational study evaluating another device, biologic, or drug&#xD;
&#xD;
         14. Presence of intramural thrombus, tumor or other abnormality or condition that&#xD;
             precludes vascular access, or manipulation of the catheter&#xD;
&#xD;
         15. Life expectancy or other disease processes likely to limit survival to less than 12&#xD;
             monthsLife expectancy or other disease processes likely to limit survival to less than&#xD;
             12 months&#xD;
&#xD;
         16. Acute Covid-19 infection (fever and/or biological inflammatory syndrome, and positive&#xD;
             test documented)&#xD;
&#xD;
         17. Patient protected (guardianship or curatorship), or deprived of liberty by a judicial&#xD;
             or administrative decision;&#xD;
&#xD;
         18. Person subject to a safeguard measure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabrina Siame</last_name>
    <phone>04 91 80 70 44</phone>
    <email>ssiame@hopital-saint-joseph.fr</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

